{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:44:34Z","timestamp":1773305074960,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004955","name":"FFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xphs.2024.10.047","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:37:32Z","timestamp":1730093852000},"page":"599-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Implications of crystal disorder on the solid-state stability of olanzapine"],"prefix":"10.1016","volume":"114","author":[{"given":"Jayant","family":"Iyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-310X","authenticated-orcid":false,"given":"Jo\u00e3o F.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-7828","authenticated-orcid":false,"given":"Amrit","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.10.047_bib0001","series-title":"Accelerated Predictive Stability (APS): Fundamentals and Pharmaceutical Industry Practices","year":"2018"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.047_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01687-z","article-title":"Understanding concomitant physical and chemical transformations of simvastatin during dry ball milling","volume":"21","author":"Modhave","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2024.10.047_bib0003","unstructured":"Nokhodchi A, Javadzadeh Y. The effect of storage conditions on the physical stability of tablets. Pharm Technol"},{"key":"10.1016\/j.xphs.2024.10.047_bib0004","doi-asserted-by":"crossref","unstructured":"Loftsson T. Drug stability for pharmaceutical scientists.; 2013. doi:10.1016\/C2012-0-07703-4","DOI":"10.1016\/C2012-0-07703-4"},{"key":"10.1016\/j.xphs.2024.10.047_bib0005","unstructured":"Ekoja A. Degradation pathway of pharmaceutical dosage forms. 2017;6(12):517-521."},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/pharmaceutics14020325","article-title":"Oxidation of drugs during drug product development: problems and solutions","volume":"14","author":"Gabri\u010d","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.10.047_bib0007","first-page":"48","article-title":"Available guidance and best practices for conducting forced degradation studies","author":"Reynolds","year":"2002","journal-title":"Pharm Technol"},{"issue":"11","key":"10.1016\/j.xphs.2024.10.047_bib0008","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/mp5003976","article-title":"In silico prediction of pharmaceutical degradation pathways: a benchmarking study","volume":"11","author":"Kleinman","year":"2014","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.047_bib0009","first-page":"86","article-title":"An introduction to the accelerated stability assessment program (ASAP)","volume":"20","author":"Rack","year":"2017","journal-title":"Am Pharm Rev"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41120-020-00034-7","article-title":"Utilization of risk-based predictive stability within regulatory submissions; industry's experience","volume":"6","author":"McMahon","year":"2020","journal-title":"AAPS Open"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1520-6017(200103)90:3<253::AID-JPS1>3.0.CO;2-W","article-title":"Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition","volume":"90","author":"Hovorka","year":"2001","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0012","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/pharmaceutics14020325","article-title":"Oxidation of drugs during drug product development: problems and solutions","volume":"14","author":"Gabri\u010d","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0013","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1021\/acs.molpharmaceut.2c00967","article-title":"Theoretical and experimental investigation of autoxidation propensity of selected drugs in solution state","volume":"20","author":"Iyer","year":"2023","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0014","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11095-014-1463-7","article-title":"Predicting drug substances autoxidation","volume":"32","author":"Lienard","year":"2015","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1533\/9780857097927.15","article-title":"Free radical oxidation","author":"Frankel","year":"2012","journal-title":"Lipid Oxid"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/PDT-120002237","article-title":"Stabilization of pharmaceuticals to oxidative degradation","volume":"7","author":"Waterman","year":"2002","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2024.10.047_bib0017","series-title":"Organic Chemistry of Drug Degradation","first-page":"54","article-title":"Chapter 3. Oxidative degradation","author":"Li","year":"2012"},{"key":"10.1016\/j.xphs.2024.10.047_bib0018","series-title":"Pharmaceutical Stress Testing- Predicting Drug Degradation","first-page":"23","article-title":"Chapter 2. Stress testing: a predictive tool. Chapter 3. Stress testing: the chemistry of drug degradation. Chapter 6. Oxidative susceptibility testing","author":"Baertschi","year":"2011"},{"key":"10.1016\/j.xphs.2024.10.047_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.02.019","article-title":"Role of crystal disorder and mechanoactivation in solid-state stability of pharmaceuticals","author":"Iyer","year":"2023","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.047_bib0020","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1016\/j.xphs.2019.05.032","article-title":"Solid-state reactivity of mechano-activated simvastatin: atypical relation to powder crystallinity","volume":"108","author":"Modhave","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.047_bib0021","series-title":"Mechanical Activation of Secondary Processed Orally Inhaled Active Pharmaceutical Ingredients","author":"Depasquale","year":"2015"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8020017","article-title":"Nanomilling of drugs for bioavailability enhancement: a holistic formulation-process perspective","volume":"8","author":"Li","year":"2016","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.047_bib0023","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1567201816666190416123939","article-title":"Preparation, characterization and prevention of auto-oxidation of amorphous sirolimus by encapsulation in polymeric films using hot melt extrusion","volume":"16","author":"Kanaujia","year":"2019","journal-title":"Curr Drug Deliv"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0024","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jps.10066","article-title":"The effect of disorder on the chemical reactivity of an organic solid, tetraglycine methyl ester change of the reaction mechanism","volume":"91","author":"Shalaev","year":"2002","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.047_bib0025","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/mp800092t","article-title":"Solid state amorphization of pharmaceuticals","volume":"5","author":"Willart","year":"2008","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0026","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/acs.molpharmaceut.2c00841","article-title":"Mechanoactivation as a tool to assess the autoxidation propensity of amorphous drugs","volume":"20","author":"Iyer","year":"2023","journal-title":"Mol Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.047_bib0027","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.accounts.2c00062","article-title":"Toward mechanistic understanding of mechanochemical reactions using real-time in situ monitoring","volume":"55","author":"Lukin","year":"2022","journal-title":"Acc Chem Res"},{"issue":"8","key":"10.1016\/j.xphs.2024.10.047_bib0028","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1070\/RC1999v068n08ABEH000435","article-title":"Transformations of organic compounds under the action of mechanical stress","volume":"68","author":"Dubinskaya","year":"1999","journal-title":"Russ Chem Rev"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1070\/RC2006v075n03ABEH001205","article-title":"Mechanochemistry and mechanical activation of solids","volume":"75","author":"Boldyrev","year":"2006","journal-title":"Russ Chem Rev"},{"issue":"90","key":"10.1016\/j.xphs.2024.10.047_bib0030","doi-asserted-by":"crossref","first-page":"11956","DOI":"10.1039\/D1CC04716G","article-title":"Ball milling \u2013 a new concept for predicting degradation profiles in active pharmaceutical ingredients","volume":"57","author":"Kaiser","year":"2021","journal-title":"Chem Commun"},{"key":"10.1016\/j.xphs.2024.10.047_bib0031","first-page":"1","article-title":"Applying material science principles to chemical stability: modelling solid state autoxidation in mifepristone containing different degrees of crystal disorder","volume":"000","author":"Iyer","year":"2023","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0032","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/pharmaceutics15030848","article-title":"Screening autoxidation propensities of drugs in the solid-state using PVP and in the solution state using N-methyl pyrrolidone","volume":"15","author":"Iyer","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0033","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jps.2600810216","article-title":"Autoxidation of tetrazepam in tablets: prediction of degradation impurities from the oxidative behavior in solution","volume":"81","author":"Giovanni","year":"1992","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.047_bib0034","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jps.23513","article-title":"Identification of the degradation products of the steroid sulfatase inhibitor KW-2581 in jet mill-micronized powder","volume":"102","author":"Aoki","year":"2013","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jps.23339","article-title":"Mechanistic study of the oxidative degradation of the triazole antifungal agent CS-758 in an amorphous form","volume":"102","author":"Ueyama","year":"2013","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.047_bib0036","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.xphs.2021.05.013","article-title":"A co-processed API approach for a shear sensitive compound affording improved chemical stability and streamlined drug product processing","volume":"110","author":"Schenck","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.047_bib0037","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.colsurfb.2018.05.003","article-title":"Density fluctuations in amorphous pharmaceutical solids. Can SAXS help to predict stability?","volume":"168","author":"Laggner","year":"2018","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.047_bib0038","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/jps.23573","article-title":"Solid-state amorphization of linaprazan by mechanical milling and evidence of polymorphism","volume":"102","author":"Willart","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.047_bib0039","doi-asserted-by":"crossref","first-page":"11527","DOI":"10.1039\/C4CP01233J","article-title":"Effect of gamma irradiation on poly(vinyledene difluoride)-lithium bis(oxalato)borate electrolyte","volume":"16","author":"Hayati","year":"2014","journal-title":"Phys Chem Chem Phys"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.10.047_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijpharm.2005.05.035","article-title":"Thermal behaviour and stability in olanzapine","volume":"301","author":"Polla","year":"2005","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.10.047_bib0041","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2006.07.023","article-title":"Solid state characterization of olanzapine polymorphs using vibrational spectroscopy","volume":"326","author":"Ayala","year":"2006","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.10.047_bib0042","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijpharm.2016.05.038","article-title":"Role of moisture on the physical stability of polymorphic olanzapine","volume":"509","author":"Paisana","year":"2016","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0043","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jpba.2006.08.030","article-title":"Quantification of olanzapine polymorphs using powder X-ray diffraction technique","volume":"43","author":"Tiwari","year":"2007","journal-title":"J Pharm Biomed Anal"},{"issue":"August","key":"10.1016\/j.xphs.2024.10.047_bib0044","article-title":"Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation","volume":"588","author":"da Costa","year":"2020","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.047_bib0045","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/jps.20328","article-title":"Studies on the crystallinity of a pharmaceutical development drug substance","volume":"94","author":"Byard","year":"2005","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.047_bib0046","first-page":"2333","article-title":"Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns","volume":"23","author":"Zografi","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.047_bib0047","first-page":"1","article-title":"Industry white paper: contemporary opportunities and challenges in characterizing crystallinity in amorphous solid dispersions","volume":"000","author":"Chasse","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.047_bib0048","doi-asserted-by":"crossref","unstructured":"Larkin P. FTIR and Raman spectroscopy principles and spectral interpretation.; 2011.","DOI":"10.1016\/B978-0-12-386984-5.10002-3"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0049","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1208\/s12249-012-9801-8","article-title":"Mechanically induced amorphization of drugs: a study of the thermal behavior of cryomilled compounds","volume":"13","author":"Trasi","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2478\/acph-2013-0026","article-title":"Methods of amorphization and investigation of the amorphous state","volume":"63","author":"Einfalt","year":"2013","journal-title":"Acta Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2024.10.047_bib0051","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/jps.21219","article-title":"Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin","volume":"97","author":"Feng","year":"2008","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2024.10.047_bib0052","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.xphs.2019.03.017","article-title":"Using milling to explore physical states: the amorphous and polymorphic forms of sulindac","volume":"108","author":"Latreche","year":"2019","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0053","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1021\/acs.cgd.7b01664","article-title":"Using milling to explore physical states: the amorphous and polymorphic forms of dexamethasone","volume":"18","author":"Oliveira","year":"2018","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.xphs.2024.10.047_bib0054","doi-asserted-by":"crossref","unstructured":"Newman A, Zografi G. Commentary commentary : considerations in the measurement of glass transition temperatures of pharmaceutical amorphous solids. Published online 2020:1-13. doi:10.1208\/s12249-019-1562-1","DOI":"10.1208\/s12249-019-1562-1"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.047_bib0055","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1081\/DDC-120025865","article-title":"Conditioning following powder micronization: influence on particle growth of salbutamol sulfate","volume":"29","author":"Brodka-Pfeiffer","year":"2003","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0056","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jps.10320","article-title":"The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy","volume":"92","author":"Begat","year":"2003","journal-title":"J Pharm Sci"},{"issue":"80","key":"10.1016\/j.xphs.2024.10.047_bib0057","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/pol.1955.120158006","article-title":"Influence of molecular weight and degree of crosslinking on the specific volume and glass temperature of polymers","volume":"15","author":"Fox","year":"1955","journal-title":"J Polym Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0058","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(01)00098-9","article-title":"Amorphous pharmaceutical solids: preparation, characterization and stabilization","volume":"48","author":"Yu","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.10.047_bib0059","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijpharm.2018.09.027","article-title":"Correlation between molecular dynamics and physical stability of two milled anhydrous sugars: lactose and sucrose","volume":"551","author":"Smith","year":"2018","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.047_bib0060","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1021\/acs.molpharmaceut.9b00692","article-title":"Elucidating molecular-and particle-level changes during the annealing of a micronized crystalline drug","volume":"16","author":"Puri","year":"2019","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.2600650102","article-title":"Mechanisms of solid-state reactions of drugs","volume":"6","author":"Byrn","year":"1976","journal-title":"J Pharm Sci"},{"issue":"8-9","key":"10.1016\/j.xphs.2024.10.047_bib0062","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3109\/03639048409039054","article-title":"Solid state reactions - theoretical and experimental aspects","volume":"10","author":"Monkhouse","year":"1984","journal-title":"Drug Dev Ind Pharm"},{"issue":"35","key":"10.1016\/j.xphs.2024.10.047_bib0063","doi-asserted-by":"crossref","first-page":"17315","DOI":"10.1021\/jp062746a","article-title":"Solid-state kinetic models: Basics and mathematical fundamentals","volume":"110","author":"Khawam","year":"2006","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.xphs.2024.10.047_bib0064","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/jps.20926","article-title":"Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals","volume":"96","author":"Sumie Yoshioka","year":"2007","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5173(97)00068-9","article-title":"Effects of processing on the solid-state methyl transfer of tetraglycine methyl ester","volume":"152","author":"Shalaev","year":"1997","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.047_bib0066","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/jps.23115","article-title":"Kinetic model for solid-state degradation of gabapentin","volume":"101","author":"Zong","year":"2012","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0067","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpba.2011.05.003","article-title":"Identification of oxidative degradation impurities of olanzapine drug substance as well as drug product","volume":"56","author":"Rao","year":"2011","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.047_bib0068","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jps.21146","article-title":"Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations","volume":"97","author":"Baertschi","year":"2008","journal-title":"J Pharm Sci"},{"issue":"20","key":"10.1016\/j.xphs.2024.10.047_bib0069","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1556\/AChrom.20.2008.1.7","article-title":"Identification and characterization of olanzapine degradation products under oxidative stress conditions","volume":"20","author":"Hiriyanna","year":"2008","journal-title":"Acta Chromatogr"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.047_bib0070","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jps.24667","article-title":"Artifacts generated during azoalkane peroxy radical oxidative stress testing of pharmaceuticals containing primary and secondary amines","volume":"104","author":"Nefliu","year":"2015","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.047_bib0071","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jps.21489","article-title":"Solvent effects on the AIBN forced degradation of cumene: implications for forced degradation practices","volume":"98","author":"Nelson","year":"2009","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0072","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jssc.200700397","article-title":"Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS\/MS","volume":"31","author":"Rao","year":"2008","journal-title":"J Sep Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0073","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12249-023-02721-6","article-title":"Influence of crystal disorder on the forced oxidative degradation of vortioxetine HBr","volume":"25","author":"Modhave","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.047_bib0074","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/pharmaceutics16070883","article-title":"Process-induced crystal surface anisotropy and the impact on the powder properties of odanacatib","volume":"16","author":"Bade","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.xphs.2024.10.047_bib0075","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1021\/cg900696f","article-title":"Crystal habits and the variation in surface energy heterogeneity","volume":"9","author":"Ho","year":"2009","journal-title":"Cryst Growth Des"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.047_bib0076","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejps.2005.08.013","article-title":"The effect of crystal morphology and mill type on milling induced crystal disorder","volume":"27","author":"Chikhalia","year":"2006","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.047_bib0077","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1007\/s11095-006-9080-8","article-title":"Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses","volume":"23","author":"Shamblin","year":"2006","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.10.047_bib0078","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.colsurfa.2008.06.040","article-title":"The nature of crystal disorder in milled pharmaceutical materials","volume":"331","author":"Chamarthy","year":"2008","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.047_bib0079","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1208\/s12249-024-02848-0","article-title":"Accelerated predictive stability study of a pediatric drug product for a supplemental new drug application","volume":"25","author":"Rakers","year":"2024","journal-title":"AAPS PharmSciTech"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T01:36:55Z","timestamp":1734745015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022354924004970"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.10.047","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of crystal disorder on the solid-state stability of olanzapine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.10.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}